NewAmsterdam Pharma Q3 2026 net loss narrows 76% year over year to $17.39 million
NAMS•NewAmsterdam Pharma’s third-quarter 2026 net loss narrowed 76% year over year to $17.39 million, while revenue rose to $19.16 million and cash, cash equivalents and marketable securities totaled $643.1 million.
1. Quarterly results
NewAmsterdam Pharma’s third-quarter 2026 net loss narrowed 76% year over year to $17.39 million. Revenue rose to $19.16 million, primarily due to regulatory milestones under its Menarini license agreement, and cash, cash equivalents and marketable securities totaled $643.1 million at September 30.
2. Regulatory and trial milestones
European Commission marketing authorizations for Ubeslo and Evlarco marked obicetrapib’s first regulatory approval worldwide. The PREVAIL interim analysis is planned for the fourth quarter of 2026, with results expected in the first quarter of 2027.
